FASN and metabolic dysfunction-associated steatohepatitis: Based on the disease-promoting properties of the DNL pathway and palmitate, FASN is an attractive drug target to attenuate hallmarks of NASH pathogenesis driven by hepatocytes, immune cells and HSCs.